Literature DB >> 17888581

Cortical regulation of dopamine depletion-induced dendritic spine loss in striatal medium spiny neurons.

M D Neely1, D E Schmidt, A Y Deutch.   

Abstract

The proximate cause of Parkinson's disease is striatal dopamine depletion. Although no overt toxicity to striatal neurons has been reported in Parkinson's disease, one of the consequences of striatal dopamine loss is a decrease in the number of dendritic spines on striatal medium spiny neurons (MSNs). Dendrites of these neurons receive cortical glutamatergic inputs onto the dendritic spine head and dopaminergic inputs from the substantia nigra onto the spine neck. This synaptic arrangement suggests that dopamine gates corticostriatal glutamatergic drive onto spines. Using triple organotypic slice cultures composed of ventral mesencephalon, striatum, and cortex of the neonatal rat, we examined the role of the cortex in dopamine depletion-induced dendritic spine loss in MSNs. The striatal dopamine innervation was lesioned by treatment of the cultures with the dopaminergic neurotoxin 1-methyl-4-phenylpyridinium (MPP+) or by removing the mesencephalon. Both MPP+ and mesencephalic ablation decreased MSN dendritic spine density. Analysis of spine morphology revealed that thin spines were preferentially lost after dopamine depletion. Removal of the cortex completely prevented dopamine depletion-induced spine loss. These data indicate that the dendritic remodeling of MSNs seen in parkinsonism occurs secondary to increases in corticostriatal glutamatergic drive, and suggest that modulation of cortical activity may be a useful therapeutic strategy in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17888581      PMCID: PMC2094700          DOI: 10.1016/j.neuroscience.2007.06.044

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  61 in total

1.  Spine density on neostriatal neurones changes with 6-hydroxydopamine lesions and with age.

Authors:  C A Ingham; S H Hood; G W Arbuthnott
Journal:  Brain Res       Date:  1989-12-04       Impact factor: 3.252

2.  Atrophy of medium spiny I striatal dendrites in advanced Parkinson's disease.

Authors:  T H McNeill; S A Brown; J A Rafols; I Shoulson
Journal:  Brain Res       Date:  1988-07-05       Impact factor: 3.252

3.  The termination of fibres from the cerebral cortex and thalamus upon dendritic spines in the caudate nucleus: a study with the Golgi method.

Authors:  J M Kemp; T P Powell
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1971-09-30       Impact factor: 6.237

4.  Tyrosine hydroxylase-immunoreactive boutons in synaptic contact with identified striatonigral neurons, with particular reference to dendritic spines.

Authors:  T F Freund; J F Powell; A D Smith
Journal:  Neuroscience       Date:  1984-12       Impact factor: 3.590

5.  Fine structure and synaptic connections of the common spiny neuron of the rat neostriatum: a study employing intracellular inject of horseradish peroxidase.

Authors:  C J Wilson; P M Groves
Journal:  J Comp Neurol       Date:  1980-12-01       Impact factor: 3.215

Review 6.  Dopamine and synaptic plasticity in the neostriatum.

Authors:  G W Arbuthnott; C A Ingham; J R Wickens
Journal:  J Anat       Date:  2000-05       Impact factor: 2.610

7.  Dopamine receptors in the Parkinsonian brain.

Authors:  U K Rinne; P Lönnberg; V Koskinen
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

Review 8.  Description of Parkinson's disease as a clinical syndrome.

Authors:  Stanley Fahn
Journal:  Ann N Y Acad Sci       Date:  2003-06       Impact factor: 5.691

9.  Chemical and structural analysis of the relation between cortical inputs and tyrosine hydroxylase-containing terminals in rat neostriatum.

Authors:  J J Bouyer; D H Park; T H Joh; V M Pickel
Journal:  Brain Res       Date:  1984-06-08       Impact factor: 3.252

10.  Success and problems of long-term levodopa therapy in Parkinson's disease.

Authors:  C D Marsden; J D Parkes
Journal:  Lancet       Date:  1977-02-12       Impact factor: 79.321

View more
  38 in total

1.  Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss.

Authors:  Bonnie G Garcia; M Diana Neely; Ariel Y Deutch
Journal:  Cereb Cortex       Date:  2010-01-29       Impact factor: 5.357

2.  Differential structural plasticity of corticostriatal and thalamostriatal axo-spinous synapses in MPTP-treated Parkinsonian monkeys.

Authors:  Rosa M Villalba; Yoland Smith
Journal:  J Comp Neurol       Date:  2011-04-01       Impact factor: 3.215

3.  Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease.

Authors:  Giselle M Petzinger; Beth E Fisher; Sarah McEwen; Jeff A Beeler; John P Walsh; Michael W Jakowec
Journal:  Lancet Neurol       Date:  2013-07       Impact factor: 44.182

4.  An embryonic culture system for the investigation of striatal medium spiny neuron dendritic spine development and plasticity.

Authors:  Rachel D Penrod; Saïd Kourrich; Esther Kearney; Mark J Thomas; Lorene M Lanier
Journal:  J Neurosci Methods       Date:  2011-06-13       Impact factor: 2.390

5.  Enhancing neuroplasticity in the basal ganglia: the role of exercise in Parkinson's disease.

Authors:  Giselle M Petzinger; Beth E Fisher; Jon-Eric Van Leeuwen; Marta Vukovic; Garnik Akopian; Charlie K Meshul; Daniel P Holschneider; Angelo Nacca; John P Walsh; Michael W Jakowec
Journal:  Mov Disord       Date:  2010       Impact factor: 10.338

6.  Peripheral Administration of Tetanus Toxin Hc Fragment Prevents MPP+ Toxicity In Vivo.

Authors:  Natalia Moreno-Galarza; Liliana Mendieta; Victoria Palafox-Sánchez; Mireia Herrando-Grabulosa; Carles Gil; Daniel I Limón; José Aguilera
Journal:  Neurotox Res       Date:  2018-02-19       Impact factor: 3.911

7.  Treadmill exercise reverses dendritic spine loss in direct and indirect striatal medium spiny neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.

Authors:  William A Toy; Giselle M Petzinger; Brian J Leyshon; Garnik K Akopian; John P Walsh; Matilde V Hoffman; Marta G Vučković; Michael W Jakowec
Journal:  Neurobiol Dis       Date:  2013-12-05       Impact factor: 5.996

8.  Combination of diOlistic labeling with retrograde tract tracing and immunohistochemistry.

Authors:  M Diana Neely; Gregg D Stanwood; Ariel Y Deutch
Journal:  J Neurosci Methods       Date:  2009-08-25       Impact factor: 2.390

Review 9.  Differential striatal spine pathology in Parkinson's disease and cocaine addiction: a key role of dopamine?

Authors:  R M Villalba; Y Smith
Journal:  Neuroscience       Date:  2013-07-16       Impact factor: 3.590

10.  Homeostatic plasticity of striatal neurons intrinsic excitability following dopamine depletion.

Authors:  Karima Azdad; Marcelo Chàvez; Patrick Don Bischop; Pim Wetzelaer; Bart Marescau; Peter Paul De Deyn; David Gall; Serge N Schiffmann
Journal:  PLoS One       Date:  2009-09-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.